-
公开(公告)号:US20240277937A1
公开(公告)日:2024-08-22
申请号:US18645779
申请日:2024-04-25
Applicant: AMGEN INC.
Inventor: Adam B. McCullough , Basel Hasan Taha , Jimmie L. Ward , Christopher R. Folk , Steven William Badelt , Ferry Tamtoro , Huaying Yang , Mark Ka Lai Lee , Desheng Yin , Scott R. Gibson , Donald Busby , Peter V. Shultz , Keith P. Kogler
IPC: A61M5/20 , A61M5/142 , A61M5/158 , A61M5/24 , A61M5/315 , A61M5/32 , A61M5/50 , G06Q50/00 , G06Q50/22 , G16H20/17 , G16H40/00 , G16H40/63 , G16H40/67
CPC classification number: A61M5/20 , A61M5/14244 , A61M5/14248 , A61M5/158 , A61M5/24 , A61M5/31501 , A61M5/31568 , A61M5/3202 , A61M5/3243 , A61M5/3257 , A61M5/326 , A61M5/5086 , G06Q50/01 , G06Q50/22 , G16H20/17 , G16H40/00 , G16H40/63 , G16H40/67 , A61M2005/3267 , A61M2205/3331 , A61M2205/3368 , A61M2205/3553 , A61M2205/3576 , A61M2205/50 , A61M2205/502 , A61M2205/52 , A61M2205/581 , A61M2205/6009
Abstract: A drug delivery system is disclosed that includes a drug delivery device having a reservoir, a delivery cannula having a proximal end in fluid communication with the reservoir and a distal end to be received within a patient, and one or more controllable elements. The drug delivery system may further include one or more sensors coupled to the drug delivery device, and a controller coupled to the one or more sensors and the one or more controllable elements. The controller may be configured to use the one or more sensors to determine a condition or an operational state of the drug delivery device. Furthermore, the controller may be configured to control the controllable element based on the condition or the operational state of the drug delivery device and/or identity information stored in a memory onboard the device. A method for use with a drug delivery device is also disclosed.
-
公开(公告)号:US11213624B2
公开(公告)日:2022-01-04
申请号:US16843622
申请日:2020-04-08
Applicant: AMGEN INC.
Inventor: Adam B. McCullough , Ferry Tamtoro , Huaying Yang , Mark Ka Lai Lee , Desheng Yin , Scott R. Gibson , Donald Busby , Peter V. Shultz , Keith P. Kogler , Basel Hasan Taha , Jimmie L. Ward , Christopher R. Folk , Steven William Badelt
IPC: A61M5/142 , A61M5/20 , A61M5/315 , A61M5/32 , A61M5/50 , G16H20/17 , G16H40/63 , G16H40/00 , G16H40/67 , G06Q50/22 , G06Q50/00 , A61M5/158 , A61M5/24
Abstract: A drug delivery system is disclosed that includes a drug delivery device having a reservoir, a delivery cannula having a proximal end in fluid communication with the reservoir and a distal end to be received within a patient, and one or more controllable elements. The drug delivery system may further include one or more sensors coupled to the drug delivery device, and a controller coupled to the one or more sensors and the one or more controllable elements. The controller may be configured to use the one or more sensors to determine a condition or an operational state of the drug delivery device. Furthermore, the controller may be configured to control the controllable element based on the condition or the operational state of the drug delivery device and/or identity information stored in a memory onboard the device. A method for use with a drug delivery device is also disclosed.
-
公开(公告)号:US20210402083A1
公开(公告)日:2021-12-30
申请号:US17386659
申请日:2021-07-28
Applicant: AMGEN INC.
Inventor: Scott R. Gibson , Sheldon B. Moberg , Basel Hasan Taha , Margaux Frances Boyaval , Mark A. Destefano , Lawton Laurence , John C. Love , Ian B. Hanson , Paul F. Bente, IV , Matthew J. Clemente , Antonio Ubach , Rajan Ramaswamy , Daniel S. Codd , Scott Beaver , Kevin L. Bokelman , Ian P. Dardani , Sean M. O'connor , Danielle Feldman
Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.
-
公开(公告)号:US20200297927A1
公开(公告)日:2020-09-24
申请号:US16649412
申请日:2018-09-26
Applicant: AMGEN INC.
Inventor: Carl Conrath , Ali Nekouzadeh , Basel Hasan Taha
Abstract: A drug delivery device includes a housing defining a shell, a container, a drive mechanism, a needle assembly having first and second ends, a fluid flow connection, and a flow adapter, each of which is at least partially disposed within the housing. The container has first and second ends and an inner volume to contain a medicament to be administered to a user. The drive mechanism is adapted to exert a force to urge the medicament out the second end of the container. The fluid flow connection is coupled to the second end of the container and the first end of the needle assembly and is adapted to allow the medicament to flow from the container to the needle assembly. The flow adapter includes at least one protrusion for generating a minor head loss to the medicament flowing within the fluid flow connection and helps to reduce variations of injection rates due to variations in drug product viscosities.
-
公开(公告)号:US11207460B2
公开(公告)日:2021-12-28
申请号:US15775650
申请日:2016-12-14
Applicant: AMGEN INC.
Inventor: Ferry Tamtoro , Huaying Yang , Scott Robert Gibson , Donald Busby , Peter V. Shultz , Basel Hasan Taha , Adam B. McCullough
Abstract: A drug delivery system includes a storage container defining one or more storage compartments and having at least one container sensor coupled thereto, a container condition change mechanism coupled to the storage container for imparting a change on one or more conditions of the one or more storage compartments, at least one drug delivery device adapted to deliver a drug to a user and adapted to be at least partially disposed within one or more of the one or more storage compartments, at least one delivery device sensor, a delivery device condition change mechanism coupled to the drug delivery device, and a controller coupled to the storage container. The storage container may be adapted to hold a number of drug delivery devices within a number of sealable storage compartments. The container sensor is adapted to sense a condition of the storage container, and the delivery device sensor is adapted to sense a condition of the at least one drug delivery device. The controller is adapted to instruct the container condition change mechanism and/or the delivery device change mechanism to impart a change on at least one condition of the storage container and/or the drug delivery device.
-
公开(公告)号:US11129936B2
公开(公告)日:2021-09-28
申请号:US16089685
申请日:2017-04-07
Applicant: AMGEN INC.
Inventor: Scott R. Gibson , Sheldon B. Moberg , Basel Hasan Taha , Margaux Frances Boyaval , Mark A. Destefano , Lawton Laurence , John C. Love , Ian B. Hanson , Paul F. Bente, IV , Matthew J. Clemente , Antonio Ubach , Rajan Ramaswamy , Daniel S. Codd , Scott Beaver , Kevin L. Bokelman , Ian P. Dardani , Sean M. O'connor , Danielle Feldman
Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device includes a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector defines a sterile fluid flowpath between the container and the insertion mechanism. A cannula initially disposed about the needle is included.
-
公开(公告)号:US20170103186A1
公开(公告)日:2017-04-13
申请号:US15315954
申请日:2015-06-03
Applicant: AMGEN INC.
Inventor: Adam B. McCullough , Ferry Tamtoro , Huaying Yang , Mark Ka Lai Lee , Desheng Yin , Scott R. Gibson , Donald Busby , Peter V. Shultz , Keith P. Kogler , Basel Hasan Taha , Jimmie L. Ward , Steven William Badelt
CPC classification number: A61M5/20 , A61M5/14244 , A61M5/14248 , A61M5/158 , A61M5/24 , A61M5/31501 , A61M5/31568 , A61M5/3202 , A61M5/3243 , A61M5/3257 , A61M5/326 , A61M5/5086 , A61M2005/3267 , A61M2205/3331 , A61M2205/3368 , A61M2205/3553 , A61M2205/3576 , A61M2205/50 , A61M2205/502 , A61M2205/52 , A61M2205/581 , A61M2205/6009 , G06F19/325 , G06F19/3418 , G06F19/3468 , G06Q50/01 , G06Q50/22
Abstract: Systems and methods are disclosed herein for supporting a patient's use of a drug delivery device. The patient may be associated with a support group via, for example, a social networking service for the purpose of increasing the likelihood that the patient will comply with a treatment regimen. Based on data representative of a condition and/or operational state of the drug delivery device, it may be determined whether the patient is compliant with the treatment regimen. If the patient is not compliant, the systems and method disclosed herein may transmit a communication to the support group requesting the support group to counsel the patient about the treatment regimen. The counseling may take the form of words of encouragement, coaching, suggestions, reminders, and/or any other communication likely to urge the patient to comply with the treatment regimen.
-
公开(公告)号:US11266777B2
公开(公告)日:2022-03-08
申请号:US16071873
申请日:2017-02-13
Applicant: AMGEN INC.
Inventor: Scott R. Gibson , Sheldon B. Moberg , Basel Hasan Taha , Margaux Frances Boyaval , Mark A. Destefano , John C. Love , Ian B. Hanson , Paul F. Bente, IV , Matthew J. Clemente , Rajan Ramaswamy , Daniel S. Codd , Scott Beaver , Kevin L. Bokelman , Sean M. O'connor , Robert Decker , Gautam N. Shetty , Ryan M. Agard , Nicholas J. Ciccarelli , Daniel Davenport
Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.
-
公开(公告)号:US20220031939A1
公开(公告)日:2022-02-03
申请号:US17277599
申请日:2019-10-14
Applicant: AMGEN INC.
Inventor: Ali Nekouzadeh , Carl Conrath , Scott Robert Gibson , Basel Hasan Taha
Abstract: Methods, devices, and components are provided to reduce tissue resistive pressure during a subcutaneous drug delivery operation by increasing the size of the injection cavity by partially retracting the drug delivery member after inserting the drug delivery member to a subcutaneous position. The drug delivery devices described herein include a motor operably coupled to a drug delivery member. The motor can be selectively activated by a controller to retract the drug delivery member a predetermined distance to relieve pressure in an injection cavity in a patient. A force sensor can provide the controller with a drug delivery member insertion force. The controller can then estimate a tissue resistive pressure based on the drug delivery member insertion force and determine the predetermined distance for the partial drug delivery member retraction based on the tissue resistive pressure.
-
公开(公告)号:US20170119969A1
公开(公告)日:2017-05-04
申请号:US15315829
申请日:2015-06-03
Applicant: AMGEN INC.
Inventor: Adam B. McCullough , Ferry Tamtoro , Huaying Yang , Mark Ka LAi Lee , Desheng Yin , Scott R. Gibson , Donald Busby , Peter V. Shultz , Keith P. Kogler , Basel Hasan Taha , Jimmie L. Ward , Christopher R. Folk , Steven William Badelt
CPC classification number: A61M5/20 , A61M5/14244 , A61M5/14248 , A61M5/158 , A61M5/24 , A61M5/31501 , A61M5/31568 , A61M5/3202 , A61M5/3243 , A61M5/3257 , A61M5/326 , A61M5/5086 , A61M2005/3267 , A61M2205/3331 , A61M2205/3368 , A61M2205/3553 , A61M2205/3576 , A61M2205/50 , A61M2205/502 , A61M2205/52 , A61M2205/581 , A61M2205/6009 , G06F19/325 , G06F19/3418 , G06F19/3468 , G06Q50/01 , G06Q50/22
Abstract: A drug delivery system is disclosed that includes a drug delivery device having a reservoir, a delivery cannula having a proximal end in fluid communication with the reservoir and a distal end to be received within a patient, and one or more controllable elements. The drug delivery system may further include one or more sensors coupled to the drug delivery device, and a controller coupled to the one or more sensors and the one or more controllable elements. The controller may be configured to use the one or more sensors to determine a condition or an operational state of the drug delivery device. Furthermore, the controller may be configured to control the controllable element based on the condition or the operational state of the drug delivery device and/or identity information stored in a memory onboard the device. A method for use with a drug delivery device is also disclosed.
-
-
-
-
-
-
-
-
-